Autolus Therapeutics
$1.38
40
+$0.11+8.66% Tuesday 19:57
Statistics
Day High
1.43
Day Low
1.31
52W High
2.7
52W Low
1.11
Volume
3,439,557
Avg. Volume
1,888,350
Mkt Cap
367.28M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Earnings
12AugExpected
Expected EPS
-0.24
Actual EPS
-0.18
Financials
-2,180.45%Profit Margin
Unprofitable20.24MRevenue
-441.32MNet Income
Analyst Ratings
$9.67Average Price Target
The highest estimate is 10.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow AUTL. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap148.78B
Novartis
NVS
Mkt Cap237.61B
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
Allogene Therapeutics
ALLO
Mkt Cap275.13M
Precigen
PGEN
Mkt Cap1.46B
About
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Show more...
CEO
Dr. Christian Martin Itin Ph.D.
Employees
647
Country
GB
ISIN
US05280R1005
Listings
0 Comments
Share your thoughts
FAQ
What is Autolus Therapeutics stock price today?▼
The current price of AUTL is $1.38 USD — it has increased by +8.66% in the past 24 hours. Watch Autolus Therapeutics stock price performance more closely on the chart.
What is Autolus Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Autolus Therapeutics stocks are traded under the ticker AUTL.
Is Autolus Therapeutics stock price growing?▼
AUTL stock has risen by +3.76% compared to the previous week, the month change is a -19.3% fall, over the last year Autolus Therapeutics has showed a -2.13% decrease.
What is Autolus Therapeutics market cap?▼
Today Autolus Therapeutics has the market capitalization of 367.28M
What were Autolus Therapeutics earnings last quarter?▼
AUTL earnings for the last quarter are -0.18 USD per share, whereas the estimation was -0.24 USD resulting in a +25% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Autolus Therapeutics revenue for the last year?▼
Autolus Therapeutics revenue for the last year amounts to 20.24M USD.
What is Autolus Therapeutics net income for the last year?▼
AUTL net income for the last year is -441.32M USD.
How many employees does Autolus Therapeutics have?▼
As of April 01, 2026, the company has 647 employees.
In which sector is Autolus Therapeutics located?▼
Autolus Therapeutics operates in the Health Care sector.
When did Autolus Therapeutics complete a stock split?▼
Autolus Therapeutics has not had any recent stock splits.
Where is Autolus Therapeutics headquartered?▼
Autolus Therapeutics is headquartered in London, GB.